Buscar
Mostrando ítems 1-10 de 18
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
(Elsevier, 2022)
Introduction: This study aimed to examine the efficacy and safety of dapagliflozin in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial (NCT03036150) by geographic region. ...
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
(Oxford University Press, 2020)
BACKGROUND: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin ...
Chemometrics-assisted multi-instrumental techniques for investigation of interactions of dapagliflozin with normal and glycated human serum albumin: application to exploiting second-order advantage for determination of glycated human serum albumin as a biomarker for controlling diabetes
(Elsevier Science, 2021-08)
In this paper, we have collected useful information about interactions of dapagliflozin (DPA) with normal human serum albumin (HSA) and glycated HSA (GHSA) by using spectroscopic and electrochemical methods. Instrumental ...
Dapagliflozin-induced attenuation of cardiac remodeling in rats with Type 1 diabetes mellitus
(Oxford Univ Press, 2018-08-01)
Efeitos Da Dapagliflozina na Hemoglobina Glicada e no Perfil Lip??dico em Pacientes com Diabetes Mellitus Tipo 1 (DM1).
(Faculdade de Medicina da UFBAUFBAbrasil, 2017-02-07)
A new HPLC–MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers
(2019-01-01)
Monitoring the plasma concentrations of metformin and sodium-glucose cotransporter-2 inhibitors (canagliflozin, dapagliflozin and empagliflozin) is essential for pharmacokinetic and bioequivalence studies and therapeutic ...
Efeitos Da Dapagliflozina na Hemoglobina Glicada e no Perfil Lipídico em Pacientes com Diabetes Mellitus Tipo 1 (DM1).
(Faculdade de Medicina da UFBAUFBAbrasil, 2017-02-07)
O diabetes mellitus tipo 1 (DM1) uma doen a autoimune caracterizada por uma falta acentuada de insulina devido destrui ão por
autoanticorpos das c lulas beta-pancre ticas. Cerca de 50% dos pacientes
com DM1 são ...
The validity of cost-effectiveness analyses of tight glycemic control. A systematic survey of economic evaluations of pharmacological interventions in patients with type 2 diabetes
(Springer, 2020)
PURPOSE: Currently available randomized trial evidence has shown no reductions in type 2 diabetes (T2D) complications important to patients with tight glycemic control. Yet, economic analyses consistently find tight ...